Despite the success of antiretroviral therapy (ART), latent HIV-1 continues to persist in a long-lived population of resting memory CD4+ T cells within those who are infected. Finding a safe and effective means to induce latency reversal (LR) during ART to specifically expose this latent HIV-1 cellular reservoir for immune elimination has been a major barrier to a functional cure.
Pubmed ID: 30952614 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
NIH HIV Reagent Program has been managed under contract by American Type Culture Collection (ATCC) since 2020. ATCC shall maintain the NIH HIV Reagent Program through identification, acquisition, production, receipt, storage, maintenance, distribution and disposal of biological and chemical research organisms and materials for HIV and other infectious diseases for use in basic and translational research.
View all literature mentionsCell line U-118MG is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsThis monoclonal targets CD14
View all literature mentionsThis monoclonal targets CD8
View all literature mentionsThis monoclonal targets CD252
View all literature mentionsThis monoclonal targets CD15
View all literature mentionsThis monoclonal targets IFN-γ
View all literature mentionsThis monoclonal targets CD107a (LAMP-1)
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD40LG
View all literature mentionsThis monoclonal targets CD209
View all literature mentionsThis unknown targets Human CD3
View all literature mentionsThis monoclonal targets Human CCR7
View all literature mentionsCell line TZM-bl is a Cancer cell line with a species of origin Homo sapiens
View all literature mentionsThis monoclonal targets CD8
View all literature mentions